Articles From: iShares Leads Global ETF Industry Flows with $102.8bn in 2014 to Israel to Assess Whether Noble, Delek Have Monopoly in Gas Sector


BlackRock, Inc. (NYSE: BLK) announced today that its iShares business led the global industry by capturing $102.8bn in new flows in 2014, 31% of the record-breaking $330.7bn global exchange traded fund (ETF) market flows.
Sign-up for iShares Leads Global ETF Industry Flows with $102.8bn in 2014 investment picks
As of December 9, 2014, iShares MSCI ACWI Low Carbon Target ETF (CRBN) began participating in the NYSE Arca ETP Program on its listing market, NYSE Arca.
Sign-up for iShares MSCI ACWI Low Carbon Target ETF (CRBN) to Participate in NYSE Arca ETP Incentive Program investment picks
-- Collaboration Combines Isis' RNA-Targeted Technology With Expertise of Janssen in Autoimmune Disorders and Therapeutic Formulation --
Sign-up for Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract investment picks
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics investment picks
Isis Strengthens Management Team Adding Strategic Business and Strategic Marketing Expertise CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer investment picks
AstraZeneca advances ISIS-STAT3 Rx in Clinical Development CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca investment picks
ISIS-DMPK Rx Extends the Targeting of Antisense Drugs to Include Muscle Tissue CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1 investment picks
-- Isis Earns $27 Million Milestone Payment --
Sign-up for Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy investment picks
2014/11/7
-- Conference Call Webcast Friday, November 7, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014 investment picks
2014/12/7
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin Data published in New England Journal of Medicine and featured at the American Society of Hematology annual meeting Isis to host a webcast at 9:00 a.m. ET on Monday, December 8, 2014 CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery investment picks
Isis Pharmacueticals Inc. (ISIS) said Thursday it expects to "significantly" improve on its 2014 guidance, ending the year with a pro forma net operating loss in the mid to high teens and more than $725 million cash.
Sign-up for Isis Pharmaceuticals shares rise 2.8% after company raises outlook investment picks
Strong Performance represents success of novel business strategy CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance investment picks
2014/11/18
- Webcast scheduled on Monday, December 8 at 9:00 a.m. Eastern Time CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting investment picks
CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference investment picks
CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals to Present at Upcoming Investor Conferences investment picks
Substantial reductions of up to 86% in triglycerides observed All patients achieved a triglyceride level First study to support the role of apoC-III as a key regulator of triglyceride metabolism utilizing multiple pathways CARLSBAD, Calif.
Sign-up for ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine investment picks
ST. LOUIS , Dec.
Sign-up for Isle Of Capri Casinos, Inc. Announces Fiscal 2015 Second Quarter Results investment picks
ST. LOUIS , Nov.
Sign-up for Isle Of Capri Casinos, Inc. Will Report FY 2015 Second Quarter Results investment picks
2014/12/3
Islet Holdings, Inc. (Pink Sheets:ISHI)(“the Company”) recently announced that the Company would expand its business plan to pursue additional and new medical technologies and products.
Sign-up for Islet Holdings, Inc. Adds New Business Pursuits investment picks
2015/1/6
Kenon's shares will commence trading on the NYSE on or about January 6, 2015 on a when-issued basis under the symbol "KEN WI" SINGAPORE , Jan.
Sign-up for Israel Corporation Approves Spin-Off of Kenon investment picks
TEL AVIV, Israel , November 25, 2014 /PRNewswire/ -- ILCO announces shareholders' meeting to be held on December 31st to approve the proposed separation of its holdings, and publishes full transaction report detailing the process and proposed new structure ILCO's new strategic focus following the separation will be on its remaining public holdings, Israel Chemicals (NYSE:ICL, TASE:ICL) and Bazan (TASE:ORL), and it will refrain from investing in new companies.
Sign-up for Israel Corporation Moves Forward With the Proposed Strategic Separation of its Holdings investment picks
2014/12/23
By Sara Toth Stub Tel Aviv--Israel's antitrust authority is to consider whether Noble Energy Ltd.
Sign-up for Israel to Assess Whether Noble, Delek Have Monopoly in Gas Sector investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: iShares Leads Global ETF Industry Flows with $102.8bn in 2014 to Israel to Assess Whether Noble, Delek Have Monopoly in Gas Sector
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent